Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.61 |
| ▸ | BCHE | P06276 | 9/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.48 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.48 |
| ▸ | CASR | P41180 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436055 | 1.00 | ACHE (0.61) | ACHEBCHEFAAHAOC3L3MBTL1 | |
| SCHEMBL2439189 | 1.00 | ACHE (0.61) | ACHEBCHEFAAHAOC3L3MBTL1 | |
| SCHEMBL30881618 | 1.00 | ACHE (0.61) | ACHEBCHEFAAHAOC3L3MBTL1 | |
| SCHEMBL19058795 | 0.86 | ACHE (0.54) | ACHEBCHEFAAHAOC3L3MBTL1 | |
| SCHEMBL19058701 | 0.85 | CASR (0.56) | AOC3L3MBTL1TRPM8CASR | |
| SCHEMBL2892838 | 0.85 | CASR (0.56) | AOC3L3MBTL1TRPM8CASR | |
| Mandelic Acid SCHEMBL4873771 | 0.84 | ACHE (0.57) | ACHEBCHEFAAHTRPM8MARK4 | |
| Mandelic Acid SCHEMBL2436177 | 0.84 | ACHE (0.57) | ACHEBCHEFAAHTRPM8MARK4 | |
| SCHEMBL6940584 | 0.82 | AOC3 (0.54) | ACHEAOC3L3MBTL1CASR | |
| SCHEMBL18297336 | 0.80 | ACHE (0.53) | ACHEBCHEFAAHAOC3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1980552-A2 | A process for the preparation of rivastigmine or a salt thereof | Dr. Reddy's Laboratories Ltd. (IN) | 2008-10-15 | — | — | EP | claimed |
| US-8013181-B2 | Reacting S-(-)-[1-(3-hydroxyphenyl)ethyl]dimethylamine with N-ethyl-N-methyl carbamoyl chloride in the presence of an organic base | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-09-06 | — | — | US | disclosed |
| US-7531684-B2 | Process for making aminoalkylphenyl carbamates and intermediates therefor | SYNTHON BV (NL) | 2009-05-12 | — | — | US | disclosed |
| US-20080255383-A1 | PREPARATION OF RIVASTIGMINE AND ITS SALTS | DR. REDDY'S LABORATORIES, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1980552-A2 | A process for the preparation of rivastigmine or a salt thereof | Dr. Reddy's Laboratories Ltd. (IN) | 2008-10-15 | — | — | EP | disclosed |
| US-20080154057-A1 | PROCESS FOR MAKING AMINOALKYLPHENYL CARBAMATES AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255383-A1 | PREPARATION OF RIVASTIGMINE AND ITS SALTS | ACHE, EHMT1, BCHE | ACHE 1/4885BCHE 3/4885FAAH 1322/4885 |
| US-20080154057-A1 | PROCESS FOR MAKING AMINOALKYLPHENYL CARBAMATES AND INTERMEDIATES THEREFOR | ACHE, BCHE, NOTUM | ACHE 1/4885BCHE 2/4885FAAH 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.